Calcitriol

Selected oral labels cover secondary hyperparathyroidism/resultant metabolic bone disease in moderate-to-severe chronic renal failure before dialysis (label Ccr 15–55 mL/min, pediatric values corrected to 1.73 m²), dialysis-associated hypocalcemia/metabolic bone disease, and hypocalcemia from postsurgical or idiopathic hypoparathyroidism or pseudohypoparathyroidism. This labeling is not a recommendation to give calcitriol routinely to every patient with CKD or low nutritional vitamin D.

Selected IV injection treats hypocalcemia in chronic renal dialysis and lowers elevated PTH; it is not the oral predialysis or skin product. Vectical treats mild-to-moderate plaque psoriasis in adults and children ≥ 2 years. Vectical’s safety/effectiveness with known or suspected calcium-metabolism disorders has not been evaluated; it is not treatment for hypocalcemia.

KDIGO suggests against routine calcitriol in adults with nondialysis CKD G3a–G5, reserving it for severe, progressive hyperparathyroidism in G4–G5. For G5D requiring PTH-lowering treatment, calcitriol is one option alongside calcimimetics/other vitamin D analogs or combinations. Evaluate the full mineral/PTH picture and reversible causes rather than treating one isolated result. This guidance is distinct from the older product-label indication wording.

Doses below are mcg, except the explicitly stated ng/kg pediatric start. Start low and titrate with laboratory assessment; do not impose a universal calcium supplement amount. The liquid is 1 mcg/mL and requires accurate metric measurement. Selected capsules contain 0.25 mcg; higher daily doses require the prescribed number of capsules or another verified product.

IV use only: usual initial 1–2 mcg three times weekly, approximately every other day; the label also expresses 1 mcg as 0.02 mcg/kg. Initial doses from 0.5–4 mcg have been used, not a direction that every patient should start at 4 mcg. If response is inadequate, increase by 0.5–1 mcg at 2–4 week intervals, guided by calcium, phosphorus, and PTH. Obtain calcium/phosphorus at least twice weekly during titration; stop for hypercalcemia, correct abnormalities, and restart lower only under supervision. Pediatric data are limited to the label’s adolescent study and do not establish a universal pediatric regimen.

Systemic labels retain a calcium×phosphate product limit of 70 mg²/dL²; the IV label also describes a PTH range 1.5–3 times the assay upper limit and reduction/holding when over-suppressed. KDIGO instead guides CKD decisions using individual calcium/phosphate values together and trends, and suggests iPTH approximately 2–9 times the assay upper limit in G5D. These are different source frameworks, not interchangeable universal goals. The nephrology plan must reconcile the product instructions with the patient’s current CKD-MBD assessment.

Apply to affected body areas twice daily, morning and evening, gently rubbing in. Age 2–6: maximum 100 g/week; age ≥ 7 and adults: maximum 200 g/week. Do not apply to eyes, lips, or facial skin; not oral, ophthalmic, or intravaginal. Occlusion increases absorption and calcium risk; use only as directed, with no invented microgram conversion into an oral/IV treatment dose.

Systemic hypercalcemia requires stopping calcitriol and assessing calcium intake/supplements and other contributing treatment. Oral labels direct daily calcium/phosphate assessment during hypercalcemia and a lower regimen after normalization; predialysis guidance differs by the prior 0.25/0.5 mcg schedule. IV dosing also decreases as PTH response changes to avoid adynamic bone disease. Stop Vectical until abnormal calcium-metabolism parameters normalize. Do not self-adjust calcium, vitamin D, or a dialysis regimen.

Oral/IV labels contraindicate hypercalcemia, evidence of vitamin D toxicity, and known hypersensitivity to calcitriol or product excipients; oral labeling also refers to drugs of the same class. Vectical’s formal contraindications section says none. Its calcium-metabolism limitation and warnings are not silently turned into systemic-product contraindications.

None of these selected U.S. labels contains a boxed warning. Hypercalcemia and the need for close titration monitoring remain central safety requirements.

Systemic toxicity commonly reflects hypercalcemia: weakness, nausea/vomiting, constipation, thirst/polyuria, anorexia, and confusion, progressing to kidney injury, calcification, or arrhythmia. Hypersensitivity is reported. Vectical can cause skin discomfort, itching/burning, erythema/blistering, hypercalciuria, and calcium laboratory abnormalities. Suspected overdose or symptomatic hypercalcemia needs medical assessment, interruption of excess exposure, and individualized supportive/mineral management; do not wait for severe symptoms or use a home antidote. Topical drug can be absorbed sufficiently to cause systemic effects.

Uncontrolled extra calcium and pharmacologic vitamin D can add hypercalcemia risk. Thiazides reduce calcium excretion; use cautiously with appropriate monitoring. Hypercalcemia can precipitate arrhythmia in patients on digitalis. Topical Vectical also cautions about thiazides, calcium, and high-dose vitamin D; do not assume local use has no interaction potential.

Avoid magnesium-containing antacids in chronic renal dialysis as directed by oral labels; IV labeling advises caution/avoidance because hypermagnesemia can develop. Cholestyramine may reduce oral absorption. Anticonvulsants can reduce vitamin D effects; assess response rather than make an automatic dose increase. Corticosteroids oppose calcium-absorption/bone effects. Adjust phosphate binders to serum phosphate; use nonaluminum binders as labeled in dialysis. Oral labels describe ketoconazole effects on endogenous calcitriol but lack an established in-vivo exogenous-drug interaction regimen.

Systemic labels retain limited controlled pregnancy data, animal developmental findings, and benefit-risk advice; excessive maternal dosing can affect neonatal calcium. Oral labels instruct mothers not to nurse during treatment, while IV labeling calls for a nursing-versus-drug decision based on maternal need. Vectical’s human reports have not identified a drug-associated major-outcome signal but do not establish zero risk; topical milk/infant effects are unknown, so assess benefits/risks and avoid application directly to nipple/areola. These are route-specific label statements, not a claimed modern lactation consensus.

Oral predialysis pediatric use has supportive evidence, but oral pediatric dialysis safety/effectiveness is not established. Hypoparathyroidism dosing below 1 year and pseudohypoparathyroidism below 6 years remain unestablished. IV data describe a small 12-week hemodialysis study in ages 13–18, not broad infant/child dosing approval. Vectical is established from 2 years with the age-specific weekly limits. Older systemic-treatment patients require cautious selection and mineral/renal assessment; topical trials did not identify overall age-based differences.

Oral/IV use is intended for specific kidney/mineral conditions and titrated to biochemical response, not a generic CrCl reduction algorithm. Oral calcitriol half-life can at least double in chronic renal failure/hemodialysis. Controlled hepatic-impairment studies are lacking; no validated hepatic-stage schedule is supplied. Vectical has no established quantitative renal/hepatic adjustment table and calcium-disorder populations are unstudied. Respect these evidence limits instead of extrapolating oral/IV doses to skin use.

Calcitriol promotes intestinal calcium absorption and influences bone, renal calcium handling, and parathyroid function, including suppression of PTH synthesis/secretion. It is already the active metabolite rather than a precursor requiring renal activation. Vectical binds vitamin D receptors, but its precise antipsoriatic mechanism is not completely established.

Oral calcitriol is rapidly absorbed, with peak levels typically 3–6 hours after a dose, extensive vitamin D-binding-protein binding, and about 5–8 hour serum half-life in healthy subjects; renal disease prolongs elimination. Metabolism, enterohepatic recycling, and predominantly fecal metabolite excretion occur. IV bolus is rapidly available and its labeled pharmacologic activity lasts about 3–5 days. Topical application can increase systemic exposure; pediatric skin trials generally found levels comparable with endogenous baseline, but that does not establish no absorption or protection from hypercalcemia.

Oral label titration requires calcium at least twice weekly, then generally monthly once stable; predialysis labs initially include calcium, phosphate, alkaline phosphatase, creatinine, and iPTH, followed by monthly mineral/renal checks for 6 months and periodic checks thereafter, with iPTH every 3–4 months. Hypoparathyroidism additionally needs periodic 24-hour urinary calcium. IV titration needs calcium/phosphate at least twice weekly with PTH and other mineral assessment to avoid over-suppression. Increase monitoring when unstable or changing doses. For skin therapy assess calcium-risk medicines, quantity/occlusion, local response, and abnormal calcium symptoms/parameters; its label does not give a universal laboratory interval.

Use the exact microgram strength/route and measure oral solution accurately; do not confuse mcg with mg or pediatric ng/kg. Avoid unapproved extra calcium, vitamin D, or magnesium antacids during dialysis. Report weakness, vomiting/constipation, unusual thirst/urination, confusion, or palpitations for hypercalcemia assessment. Follow the clinician’s diet/fluid and laboratory plan. For Vectical, respect weekly gram limits, avoid face/eyes/lips and nipple/areola while breastfeeding, avoid unapproved coverings, and do not swallow or inject the ointment.

Selected Hikma 0.25 mcg capsules are yellow oval softgel marked 547, NDC 0054-0007-13 (30) or 0054-0007-25 (100). ANI clear/colorless-to-pale-yellow oral solution 1 mcg/mL is supplied in 15 mL amber bottles with 20 single-use graduated oral dispensers, NDC 70954-831-10. Fosun IV 1 mcg/mL has 1 mL fill in 2 mL single-dose vials, carton of 10 NDC 72266-251-10. Vectical 3 mcg/g is supplied in 100 g aluminum tubes, NDC 0299-2012-10. Other brands/manufacturers require their own appearance/package check.

Covered products: oral 0.25 mcg capsule; oral 1 mcg/mL solution; IV 1 mcg/mL injection; topical 3 mcg/g ointment. Other capsule strengths, injection concentrations, compounded preparations, and calcifediol/cholecalciferol/ergocalciferol products are not substituted by this reference. “Rocaltrol,” “Calcijex,” or “Vectical” terminology does not establish availability or route equivalence.

Hikma capsules: 20–25°C, protect from light. ANI oral solution: 25°C with 15–30°C excursions, protect from light, use the supplied single-use dispenser as directed. Fosun IV: 20–25°C, protect from light, inspect for particles/discoloration, discard unused vial contents. Vectical: 20–25°C with 15–30°C excursions; do not freeze or refrigerate. Keep routes clearly identified and out of children’s reach; no unsupported opened-bottle discard duration is supplied.